Rowland Cheng advises Chinese and international clients on a range of corporate and finance transactions.
Mr. Cheng regularly represents international financial institutions, strategic investors, and Chinese corporations in a wide range of transactions, including:
- Private equity and venture investments
- Mergers and acquisitions
- Joint ventures
- Secured and unsecured financings
Mr. Cheng began practicing in the Los Angeles office of Latham & Watkins and was previously resident in the firm's offices in Hong Kong, Singapore, and San Francisco.
Mr. Cheng’s representative transactions include advising:
- Genesis MedTech, an Asia-based healthcare platform which seeks to bring innovative medical technology to the PRC market, in its acquisition of Hua MedTech, a provider of integrated healthcare solutions to stroke patients based in China
- Shockwave Medical, Inc., a pioneer in the development of intravascular lithotripsy to treat severely calcified cardiovascular disease, in its joint venture with Genesis MedTech to bring coronary and peripheral IVL to patients in China
- Corvus Pharmaceuticals, Inc., in the formation of Angel Pharmaceuticals, a new China-based biopharmaceutical company launched with PRC investors including Tigermed and Hisun Pharmaceuticals to bring innovative Corvus clinical-stage candidates to China
- Ascential plc, the FTSE 250 specialist information, data, and analytics company, on the acquisitions of Yimian Data, a Chinese digital commerce data solutions provider; Hangzhou Duozhun Data Technology, a company specializing in media trading execution in China; and 4K miles, a digital commerce advertising business serving Chinese brands trading on Amazon marketplace
- Amgen in its US$2.7 billion investment in and strategic collaboration with Beijing-based BeiGene focused on developing and commercializing oncology treatments in China
- Calysta in the formation of a joint venture with Bluestar Adisseo to commercialize proprietary aquaculture feedstock products in the PRC and Asia-Pacific
- Juno Therapeutics, in the establishment with Wuxi AppTec and financing of the JW Biotechnology joint venture focused on developing and commercializing cell therapy technologies in China
- PV Capital in the sale to Yunfeng Capital of Enova Holdings, the China rights holder for Formula E series of electric car races
- Mattel, Inc. in its joint venture and strategic collaboration with Babytree for China-based child development and learning centers
- Boston Scientific Corporation in connection with its joint venture investment into and restructuring of Suzhou Frankenman, a Chinese developer of therapeutic devices
- Dick Cook Studios (DCS) in connection with the US$650 million equity and film slate financings provided by CITIC and other PRC investors to capitalize DCS
- Accel Partners in its US$75 million investment in DJI, a leading Chinese drone and robotics manufacturer
- Nature’s Sunshine Products in its joint venture with and PIPE investment by Shanghai Fosun Pharmaceutical Co. Ltd.
- Complete Genomics, a developer of DNA sequencing products and services, in its US$118 million sale to China's BGI-Shenzhen
- Foster Wheeler Asia Pacific in its joint venture with Hebei Petrochemical Design Institute Co., a PRC state-owned contractor of chemical and petrochemical construction
- Bright Foods (Group) Co., Ltd., a Shanghai-based PRC State-owned entity operating in the foods and nutrition sector, in various transactions, including:
- US$516 million acquisition of Manassen Foods, a food producer and distributor based in Australia
- US$3 billion bid to acquire GNC Holdings, a leading US-based vitamin and supplement chain retailer
- Proposed £2.2 billion acquisition United Biscuits plc, a leading British multinational food manufacturer
- Acquisition of 60% of the equity interests in Yunnan Yinmore Sugar Company